

Supplementary materials

Supplementary Table I. CAR-T therapy in the treatment of SSc (acc. to <https://clinicaltrials.gov/>)

Study	Agents	Phase	Patient number	Population	Primary Endpoint
NCT06947460	anti-CD19 CAR-T cells	I, II	45	Refractory SLE-LN, SSc, and pSS-PAH	DLT, AEs
NCT06347718	anti-CD19 CAR-T cells	I, II	24	Systemic B Cell Mediated Autoimmune Disease	SAEs
NCT06822881	anti-CD19 CAR-T cells	I	27	Refractory SLE or SSc	DLT, AEs, SAE
NCT06792344	anti-CD19 CAR-T cells	I	12	Refractory Systemic Sclerosis	Change in the mRSS from baseline at 6 months
NCT06328777	anti-CD19 CAR-T cells	I, II	12	SSc	AEs
NCT07085104	anti-CD19 CAR-T cells	I	54	SLE, SSc, IIM	DLT, AEs
NCT06775912	anti-CD19 CAR-T cells	I	18	SLE, SSc, AAV, IIM, NMOSD, MS, MG	AEs, SAEs, AESI
NCT06931652	anti-CD70 CAR-T cells	I	11	Pediatric rheumatic diseases include JDM, SSc, SS	Safety and Tolerability EUSTAR activity index, MDAI, mRSS, of CAR-T

AAV — ANCA-associated vasculitis, AE/AEs — adverse event / adverse events, AESI — adverse events of particular concern, CAR-T — chimeric antigen receptor T-cells, CD19 — cluster of differentiation, CD70 — cluster of differentiation, DLT — dose-limiting toxicity, EUSTAR — European scleroderma trials and research group, IIM — idiopathic inflammatory myopathy, JDM — juvenile dermatomyositis, LN — lupus nephritis, MDAI — modified disease activity index, MG — myasthenia gravis, MS — multiple sclerosis, mRSS — modified Rodnan skin score, NMOSD — neuromyelitis optica spectrum disorder, pSS-PAH — primary Sjögren syndrome associated with pulmonary artery hypertension, SAE/SAEs — serious adverse event / serious adverse events, SLE — systemic lupus erythematosus, SS — Sjögren's syndrome, SSc — systemic sclerosis.